F-3 424B2 EX-FILING FEES 333-288301 0001395064 TAKEDA PHARMACEUTICAL CO LTD 0001395064 2025-06-26 2025-06-26 0001395064 1 2025-06-26 2025-06-26 0001395064 2 2025-06-26 2025-06-26 0001395064 3 2025-06-26 2025-06-26 0001395064 4 2025-06-26 2025-06-26 iso4217:USD xbrli:pure xbrli:shares

Calculation of Filing Fee Tables

F-3

TAKEDA PHARMACEUTICAL CO LTD

Table 1: Newly Registered and Carry Forward Securities

Security Type

Security Class Title

Fee Calculation or Carry Forward Rule

Amount Registered

Proposed Maximum Offering Price Per Unit

Maximum Aggregate Offering Price

Fee Rate

Amount of Registration Fee

Carry Forward Form Type

Carry Forward File Number

Carry Forward Initial Effective Date

Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward

Newly Registered Securities
Fees to be Paid 1 Debt $1,650,000,000 5.200% Guaranteed Notes due 2035 457(r) 1,650,000,000 $ 0.9964 $ 1,644,126,000.00 0.0001531 $ 251,715.69
Fees to be Paid 2 Debt $750,000,000 5.900% Guaranteed Notes due 2055 457(r) 750,000,000 $ 0.9973 $ 748,005,000.00 0.0001531 $ 114,519.57
Fees to be Paid 3 Other Guarantee of $1,650,000,000 5.200% Guaranteed Notes due 2055 Other 0.0001531 $ 0.00
Fees to be Paid 4 Other Guarantee of $750,000,000 5.900% Guaranteed Notes due 2055 Other 0.0001531 $ 0.00
Fees Previously Paid
Carry Forward Securities
Carry Forward Securities

Total Offering Amounts:

$ 2,392,131,000.00

$ 366,235.26

Total Fees Previously Paid:

$ 0.00

Total Fee Offsets:

$ 0.00

Net Fee Due:

$ 366,235.26

Offering Note

1

Final prospectus supplement.

2

See footnote 1 above.

3

See footnote 1 above. Takeda Pharmaceutical Company Limited will fully and unconditionally guarantee the notes listed above. No separate consideration will be received therefor. Pursuant to Rule 457(n) under the Securities Act of 1933, as amended, no separate fee is payable with respect to such guarantees.

4

See footnotes 1 & 3 above.
Narrative Disclosure
The maximum aggregate offering price of the securities to which the prospectus relates is $2,392,131,000.00. The prospectus is a final prospectus for the related offering.